Eris Lifesciences Limited has informed the Exchange regarding 'INSPECTION OF SWISS PARENTERALS UNITS 1 AND 2 BY HALMED, CROATIA'.
ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.5 pts less than Nifty Smallcap 250 and 3.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
HALMED, Croatia's drug regulatory agency, inspected Swiss Parenterals Ltd.'s manufacturing units in Ahmedabad from March 9-13, 2026. The inspection covered Unit 1 (general liquid and dry powder injectables) and Unit 2 (betalactam dry powder injectables). The company received non-compliance observations, which it describes as procedural in nature related to GMP compliance under EU Directive 2017/1572. Eris plans to submit corrective and preventive actions (CAPAs) and request a follow-on inspection to reinstate approvals. The company states business impact is minimal, though there will be delays in commercializing its EU CDMO product pipeline.
The regulatory scrutiny is a setback for the company's EU market expansion plans, though the company downplays the impact on existing business. Shareholders should monitor whether the follow-on inspection resolves the issues without further delays.